Announcement of the Launch of Glufast ®OD Tab. (Orally Disintegrating Tablets)

KISSEI PHARMACEUTICAL CO., LTD.

Kissei Pharmaceutical Co., Ltd. (Head Office: Matsumoto-city, Nagano, Japan; Chairman and CEO: Mutsuo Kanzawa) announced that they launch Glufast^® OD Tab. 5mg and Glufast^® OD Tab. 10mg (generic name: mitiglinide calcium hydrate, hereinafter referred to as the "drug") on June 17.

The drug is a new dosage form of Glufast^® 5mg and 10mg Tab. and is the first rapid-acting insulin secretagogue in the form of orally disintegrating tablets. Glufast^® was created and developed by Kissei and has been on the market since May 2004. As the drug rapidly disintegrates in the oral cavity and can be taken with or without water it should make taking the drug 3 times daily just before meals, a special feature of Glufast^®, even more convenient. It will also be highly suitable for patients with difficulty in swallowing tablets.

Classified as a rapid-acting insulin secretagogue, Glufast^® is a drug for the treatment of type 2 diabetes. It improves postprandial hyperglycemia by bringing insulin secretion closer to its natural patterns, and improves levels of HbA1c, an indicator of average blood glucose levels.

Kissei expects that the additional dosage form of Glufast^® will increase convenience for patients and further enhance our contribution to health care.


〈Glufast^® OD Product Reference〉

Brand Name:
Glufast^® OD Tab. 5mg
Glufast^® OD Tab. 10mg

Generic Name:
Mitiglinide calcium hydrate

Indications:
Type 2 diabetes

Dosage and administration:
The recommended usual oral dose in adults is 10 mg (as mitiglinide calcium hydrate) 3 times daily just before meals. The dose may be increased or decreased depending on the condition of the patient.

NHI price:
Glufast^® OD Tab. 5mg ¥30.80
Glufast^® OD Tab. 10mg ¥54.30

Date of NHI price listing: June 17, 2016

Date of launch: June 17, 2016

Manufactured and Distributed by:
KISSEI PHARMACEUTICAL CO., LTD.